Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

umeclidinium

- PMLiVE

Roche survey says Scottish cancer patients moving house to get treatment

But NHS Scotland hits back at report's "extremely dubious" findings

- PMLiVE

FDA committee turns down Aveo/Astellas’ cancer drug

Tivozanib unable to prove superiority to Bayer's Nexavar

- PMLiVE

FDA says Janssen’s myeloma drug is a ‘breakthrough therapy’

Should speed up regulatory process for daratumumab

- PMLiVE

GSK submits COPD drug in US and EU

Umeclidinium bromide intended as monotherapy for lung condition

- PMLiVE

Union calls on AstraZeneca to reconsider Alderley Park plans

Unite says move to Cambridge will take years to deliver value

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

Novartis building

Novartis hit by kickback lawsuits in US

Company accused of paying millions of dollars to doctors in exchange for prescribing drugs

- PMLiVE

Two new cancer drugs recommended in Europe

CHMP backing for Roche's Erivedge and Astellas' Xtandi

Novartis building

NICE turns down Novartis’ blood cancer drug Jakavi

Uncertainties remain about drug’s cost-effectiveness, according to final draft guidance

- PMLiVE

AstraZeneca sales hit by Seroquel generics

End of patent exclusivity for antipsychotic among key factors dragging down revenues

- PMLiVE

Boehringer: Move towards trial transparency is “irreversible”

Pharma company plans to publish all scientific data

- PMLiVE

Boehringer to restructure in Southern Europe

Closes chemical plant in France as part of plans to “adapt” business structure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links